Zydus Of India, Teva Of Israel Settle Two Generics Disputes
This article was originally published in PharmAsia News
Executive Summary
India's ZydusCadila and Israel's Teva have reached a settlement of generics makers over a patent dispute involving the active pharmaceutical ingredients of multinational company antipsychotic drugs. Zydus and Teva had squabbled over competing generics to be marketed in the United States, but the settlement allows Zydus to sell its versions without facing a legal challenge by Teva. The API at issue is carvedilol, used in GlaxoSmithKline's Coreg, which lost its patent protection last year. Zydus had sued Teva over a generic of Johnson & Johnson's Risperdol (risperidone), accusing the Israeli company of antitrust and deceptive filings with the U.S. Patent and Trademark Office. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.